echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > PD-1: The name is still in hand.

    PD-1: The name is still in hand.

    • Last Update: 2020-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Wen-Man PD-1 (CD279) is an inhibitory body in active T cells, which maintains extrinsic immunity by combining with ligations PD-L1 and PD-L2, and also plays a role in impairing anti-tumor immunity.
    -targeted PD-1 or its matching blocking antibodies have revolutionized cancer immunotherapy, but only a small percentage of patients are currently able to produce a lasting anti-tumor response, with most patients responding only briefly or completely unresponsively.
    years, the clinical development around the PD-1 path seems to have entered a bottleneck period, and various joint treatments have not made a substantial breakthrough.
    , scientists have recently begun an in-depth study of the mechanisms by which PD-1 paths transmit inhibitory signals, hoping to find key targets that could improve treatment.
    : In a recent review of "Revisiting the PD-1 Pathway" published September 18 in the journal Science Advances, four scientists from Harvard Medical School outlined the latest advances in the mechanisms of the PD-1 pathway and discussed the implications of these new discoveries and the gaps to be filled.
    , PD-1 and its mating bodies are expressed in a variety of cells in the congenital immune and adaptive immune system, and their expression patterns have been widely studied.
    , scientists focused primarily on transcription mechanisms that induce PD-1 and its liant expression, but recent studies have found that expressions of PD-1 and PD-L1 are also regulated by post-translation modification (Figure 1).
    CRISPR-based screening revealed that the algal glycosyl metastase Fut8 regulates the expression of PD-1 on the cell surface (Figure 1A), and that T cells treated with algal glycosylation inhibitors showed stronger anti-tumor effects in the body.
    , however, the precise bio-chemical mechanism of algal glycosylation affecting the structure and function of PD-1 has yet to be clarified.
    expression of
    PD-1 may also be regulated by the E3 connective enzyme FBXO38, which mediates K48-connected polypropulation (K48-linked polybiquitination) at PD-1K233 bits and subsequent protease degradation (Figure 1B).
    figure 1 . . . post-translation modification regulation PD-1 expression . . . A. In the endodermal mesh (ER), PD-1 underlying at N49 and N74 residues, which in turn underlying algal glycosylation in the gould, causes PD-1 to continue to express and transmit inhibitory signals on the cell membrane.
    genetic loss or pharmacological inhibition of fut8, a glycosyl transferase, can reduce the glycosylation, expression and inhibitory signals of PD-1 algae, resulting in increased T-cell activity.
    B. FBXO38 Ubiganic connective enzyme mediates PD-1 Ubiganization at K233 bits, resulting in PD-1 internalization and protease degradation.
    gene knock-down or reduction of FBXO38 can lead to an increase in PD-1 expression, thereby enhancing inhibitory signaling paths and T-cell suppression.
    expression of C. PD-L1 in tumor cells can be stabilized by glycosylation.
    GSK3 beta can antagonize this mechanism by binding to the non-glycosylated form of PD-L1, resulting in T180 and S184 bit phosphate, as well as β-TrCP-mediated PD-L1 ubiquitinization and protease degradation.
    EGFR-mediated signal can inhibit phosphorylation and degradation of GSK3 beta-mediated PD-L1, promoting PD-L1 stability and immunosuppression.
    antibodies (anti-gPD-L1) targeting glycosylated PD-L1 can block interaction with PD-1 and induce the internalization and degradation of PD-L1.
    D. In cancer cells, TNFR (TNF receptor)-mediated signals cause IKK beta-mediated p65 activation and nuclear translocation, which in turn leads to CSN5 transcription, which enhances immunosuppressive activity by directly de-urination or inhibition of PD-L1 ubiturization.
    CMTM4/6 interacts with PD-L1 on the cell surface, reducing its ubimation and increasing the half-life of the PD-L1 protein.
    and stability of PD-L1 (Source: Science Advances) PD-L1 can also be regulated at translated levels through glycosylation and ubiquitinization.
    only non-sugar-based PD-L1 has been found to interact with GSK3 beta, leading to PD-L1 phosphate-dependent protease degradation (Figure 1C).
    contrast, by directly de-urination or inhibiting ubibinization and degradation of PD-L1, CSN5 (COP9 signalosome 5) is required for TNF-α-mediated PD-L1 stabilization (Figure 1D).
    2, PD-1 and its mating body interaction Figure 2 . The interaction pattern between PD-1 and PD-L1 (Source: Science Advances) As shown in Figure 2A, PD-L1 expressed on antigen-delivered cells (APCs) or tumor cells is expressed in reverse binding to PD-1 trans-binding expressed on T cells, weakening the activation of T-cells mediated by the interaction between TCR/MHC and CD28/B7-1.
    PD-1 or PD-L1 blockable antibodies can reduce T-cell suppression by blocking the reverse interaction of PD-1/PD-L1.
    As shown in Figure 2B, when PD-1 and PD-L1 are expressed together on APCs or tumor cells, PD-1 binds to PD-L1, reducing the ability of PD-L1 to bind to PD-1 transsyse expressed on T cells.
    As shown in Figure 2C, the smooth interaction of PD-L1/B7-1 on APCs or tumor cells can also disrupt the reverse binding of PD-1/PD-L1, resulting in a decrease in PD-1-mediated T-cell inhibition.
    addition, the smooth combination of PD-L1/B7-1 did not destroy the combination of B7-1 and CD28, and the co-stimulation effect of B7-1/CD28 interaction remains.
    , the smooth combination of PD-L1/B7-1 disrupts the B7-1/CTLA-4 axis.
    As shown in Figure 2D, the addition of blocking anti-PD-L1 antibodies to block PD-1/PD-L1 interactions also blocks PD-L1/B7-1 interactions, binding the released B7-1 with CTLA-4 and transmitting an inhibition signal.
    this case, blockable anti-CTLA-4 antibodies may benefit by blocking CTLA-4-mediated T-cell suppression.
    as shown in Figure 2E, the smooth interaction of PD-L1/B7-1 on APCs prevents the reverse swallowing of regulated T-cells (Treg) CTLA-4-mediated B7-1, which causes the APC surface B7-1 to be missing.
    As shown in Figure 2F, anti-PD-L1 antibodies can bind B7-1 to CTLA-4 on Tregs by interfering with PD-L1/B7-1 interactions, promoting CTL-4-mediated B7-1 trans-swallowing and weakening the co-stimulation of B7-1 mediated, thus negatively affecting immunotherapy.
    III, PD-1 signal conduction mechanism and target 1, PD-1/SHP-2 interaction PD-1 and its notation are members of the B7/CD28/CTLA-4 family, which is a type I transglobulin, sharing a model infrastructure consisting of 1 "IgV extracellary domain", 1 "trans-membrane domain" and 1 "cytosteral tail region".
    although the extracellal structure and interaction of PD-1 have been widely studied, there is very little information about its in-cell structure and signal transduction mechanism.
    PD-1's cytoplasm tail region contains two tyrosine-based structural substates: ITIM (immunoreceptor tyrosine-resedory motif) and ITSM (immunoreceptor tyrosine-basemotif).
    study has shown that PD-1 inhibitory function relies on ITSM phosphorylation tyrosine, which prioritizes the recruitment of phosphatase SHP-2 (Src homology region 2 domain-containing phosphatase-2).
    although it is generally accepted that SHP-2 is a key medium for PD-1 inhibitory function, the exact mechanism by which PD-1 is involved in the activity of SHP-2 enzymes remains unclear.
    3 summarizes the interaction between PD-1 and SHP-2, and as shown in Figure A, according to the two-step binding model, SHP-2 C-SH2 can be used with PD-1 pY-ITSM with a strong pro Combined with force, recruit PD-1 to SHP-2, while PD-1pY-ITIM binds to N-SH2 to replace N-SH2 from the PTP bit point to activate phosphatase.
    As shown in Figure B, according to the d?poly model, SHP-2 binds to two pY-ITSM residues on two PD-1 molecules through its N-SH2 and C-SH2 domains, thus forming a PD-1:PD-1 diogenes and inducing the activation of SHP-2.
    Figure 3 . Multiple studies of PD-1/SHP-2 interaction patterns (Source: Science Advances) 2, PD-1 Targeted Signal Paths Have investigated the effects of PD-1 on key signal path paths activated by TCR and co-stimulation subjects to determine how PD-1 inhibits amplification and differentiation of activated T cells, and how to inhibit the production of cytokines.
    There has been a debate about which signal path is the main target of PD-1, most studies support PD-1 mainly target TCR and TCR downstream signal cascading, but there are also studies showing that the co-stimulation of the subject CD28 is the main target of PD-1, and other studies have shown that TCR and CD28 are targeted equally by PD-1.
    , however, while the issue is controversial, there is a consensus among many scientists that SHP-2 is the only direct partner currently identified to regulate PD-1 inhibitory signals in normal T cells.
    , however, it has since been found that when SHP-2 is missing, SHP-1 phosphatase can replace SHP-2 and compensate for the inhibitory function of PD-1.
    In addition, it is worth mentioning that although PD-1-mediated signaling and functional effects mainly act on T cells, there are studies suggesting that the PD-1:PD-L1 pathrapy may also transmit signals in cancer cells.
    study found that cancer cells may use the PD-1:PD-L1 path path line to trigger mTOR signals in adjacent tumor cells to support their growth.
    , the mechanism of PD-L1 signaling and the expression of PD-L1 in cancer cells were initially thought to be the main mechanisms of cancer-mediated T-cell immunosuppression and depletion.
    , a growing body of research has shown that expression in antigen-presented myelin cells in tumor microenvironments is equally important for mediated immunosuppressive properties of tumor-specific T cells.
    the dedes and macrophages that express PD-L1 may play a leading role in mediated T-cell immunosuppression, and the expression of PD-L1 in tumor microenvirons presented in myelin cells can predict the efficacy and therapeutic outcomes of PD-L1/PD-1 blocking.
    PD-L1 can also be expressed in active T cells, but its ability to transmit signals to T cells remains controversial.
    signal conduction mediated by PD-L1 was first studied in cancer cells.
    PD-L1 is considered an immune barrier that transmits anti-apoptosis signals in cancer cells after being connected to PD-1 expressed on T cells, inducing tolerance to T-cell-mediated killing and protecting cancer cells.
    studies have shown that PD-L1 can also activate the in viscemic signaling of cancer cells in a way that does not rely on PD-1, and enhance cancer cell proliferation and survival by inhibiting autophagy and activating mTOR.
    the PD-L1 cytokine tail region has not been identified as a distinct sequence associated with signal conduction, indicating that PD-L1 uses an unconventional signal conduction base sequence.
    recently, researchers found three conservative sequences in the cytoset tail region of PD-L1, namely ,RMLDVEKC, DTSSK, and QFEET.
    note that lysine 271 and 280 in the RMLDVEKC and DTSSK subsequents are considered targets for ubiquitinization, leading to instability and downgrading of PD-L1.
    PD-L1 may also reduce ifN-mediated cytotoxicity by relying on STAT3/caspase-7 to transmit inhibitory signals to tumor cells.
    and conservative RMLDVEKC subsector is needed to reduce IFN toxicity, the DTSSK base sequence plays the role of PD-L1 functional negative regulatory factor.
    inhibition of PD-L1 expression or treatment with PD-1 antibodies is expected to make cancer cells sensitive to IFN cytotoxicity (Figure 4).
    figure 4. PD-L1 protects tumor cells from IFN-mediated cytotoxicity by signaling (Source: Science Advances) V, PD-1 Determines the differentiation and function of T cells by regulating metabolic reprogramming, which not only supports growth and proliferation, but also play a key role in driving differentiation.
    phosphate oxide is the main energy source for naïve T cells, but when activated, naïve T cells undergo metabolic reprogramming to perform aerobic glycolysis (also known as the Warburg effect), while increasing glutamine intake and decomposition metabolism to maintain the health of the effect T cells and drive the differentiation of memory T cells.
    PD-1 signaling alters metabolic reprogramming and contributes to the use of fatty acids in β-oxidation, thereby impairing glycolysis, glutamine decomposition, and the metabolism of branched chain amino acids.
    and glycolysis can block the differentiation of TH17 cells and promote the development of Tregs.
    , oxidation paths may be a metabolic checkpoint that is expected to be used to enhance PD.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.